Polycystic Kidney Disease



A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease


Condition:   Autosomal Dominant Polycystic Kidney
Intervention:   Other: High Water Intake
Sponsors:   The Rogosin Institute;   Weill Medical College of Cornell University
Recruiting


A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)


Condition:   Polycystic Kidney, Autosomal Recessive
Intervention:   Drug: Tesevatinib
Sponsor:   Kadmon Corporation, LLC
Recruiting


Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)


Condition:   Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions:   Drug: Tolvaptan;   Drug: Matching Placebo
Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting


Using Preimplantation Genetic Diagnosis in Autosomal Dominant Polycystic Kidney Disease Patients: a Multicenter Clinical Trial


Condition:   Polycystic Kidney, Type 1 Autosomal Dominant Disease
Intervention:   Procedure: Preimplantation Genetic Diagnosis
Sponsors:   Changlin Mei;   The First Affiliated Hospital of Anhui Medical University;   The First Affiliated Hospital with Nanjing Medical University;   Shandong Provincial Hospital;   Tang-Du Hospital;   Shengjing Hospital;   Second Xiangya Hospital of Central South University;   Reproductive & Genetic Hospital of CITIC-Xiangya
Recruiting


The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain


Condition:   Autosomal Dominant Polycystic Kidney Disease
Intervention:   Device: Vessix
Sponsor:   University of Chicago
Not yet recruiting


Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease


Condition:   Polycystic Kidney Disease
Interventions:   Drug: Pioglitazone;   Drug: Placebo
Sponsor:   Indiana University
Active, not recruiting


Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease


Condition:   Polycystic Kidney, Autosomal Dominant
Interventions:   Drug: Metformin;   Other: Placebo
Sponsors:   Kyongtae Ty Bae, M.D., Ph.D.;   Tufts Medical Center;   University of Maryland;   University of Southern California;   United States Department of Defense
Recruiting


Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)


Condition:   Polycystic Kidney Disease
Interventions:   Dietary Supplement: Niacinamide;   Other: Placebo
Sponsors:   University of Kansas Medical Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting


Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease


Condition:   Autosomal Dominant Polycystic Kidney Disease
Intervention:   Drug: Tolvaptan (OPC-41061)
Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
Active, not recruiting


Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease


Conditions:   Chronic Kidney Disease;   Autosomal Dominant Polycystic Kidney Disease
Interventions:   Drug: Tolvaptan (OPC-41061);   Drug: Placebo
Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
Completed


Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease


Condition:   Polycystic Kidney Disease
Intervention:   Dietary Supplement: Niacinamide
Sponsor:   Alan Yu, MB, BChir
Completed


Repository Study of Autosomal Dominant Polycystic Kidney Disease


Condition:   Autosomal Dominant Polycystic Kidney Disease
Intervention:  
Sponsors:   The Rogosin Institute;   Weill Medical College of Cornell University;   New York Presbyterian Hospital
Withdrawn


PKD Clinical and Translational Core Study


Condition:   Polycystic Kidney Disease
Intervention:  
Sponsors:   University of Maryland;   National Institutes of Health (NIH);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting


Study of Lanreotide to Treat Polycystic Kidney Disease


Condition:   Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention:   Drug: Lanreotide
Sponsors:   University Medical Center Groningen;   Leiden University Medical Center;   Erasmus Medical Center;   Radboud University
Active, not recruiting


A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)


Condition:   Polycystic Kidney, Autosomal Dominant
Intervention:   Drug: KD019 (tesevatinib)
Sponsor:   Kadmon Corporation, LLC
Active, not recruiting


Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency


Condition:   Autosomal Dominant Polycystic Kidney Disease
Interventions:   Drug: Octreotide-LAR;   Other: Saline solution.
Sponsor:   Mario Negri Institute for Pharmacological Research
Active, not recruiting


Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)


Condition:   Autosomal Dominant Polycystic Kidney Disease
Intervention:   Drug: Tolvaptan
Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
Completed


Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD


Condition:   Autosomal Dominant Polycystic Kidney Disease
Interventions:   Drug: Tolvaptan MR;   Drug: Tolvaptan IR
Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
Completed


Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease


Condition:   Autosomal Dominant Polycystic Kidney Disease
Intervention:  
Sponsors:   University of Pittsburgh;   National Institutes of Health (NIH);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed


A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]


Condition:   Autosomal Dominant Polycystic Kidney Disease
Intervention:   Drug: OPC-41061
Sponsor:   Otsuka Pharmaceutical Co., Ltd.
Completed


Polycystic Kidney Disease Data Repository


Condition:   Polycystic Kidney Disease
Intervention:  
Sponsors:   The Rogosin Institute;   Weill Medical College of Cornell University;   New York Presbyterian Hospital
Recruiting


Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease


Condition:   Autosomal Dominant Polycystic Kidney Disease
Intervention:   Drug: Tetracosactin
Sponsor:   Istanbul University
Completed


Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)


Condition:   Polycystic Kidney, Autosomal Dominant
Interventions:   Drug: pravastatin;   Drug: Placebo
Sponsors:   University of Colorado, Denver;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed


Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)


Condition:   Polycystic Kidney Disease, Autosomal Dominant
Interventions:   Drug: Tolvaptan;   Drug: Placebo
Sponsors:   Otsuka Pharmaceutical Development & Commercialization, Inc.;   Otsuka Pharmaceutical Co., Ltd.
Completed


Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)


Condition:   Polycystic Kidney, Autosomal Dominant
Intervention:   Drug: Tolvaptan
Sponsors:   Otsuka Pharmaceutical Development & Commercialization, Inc.;   Otsuka Pharmaceutical Co., Ltd.
Completed

Refine Your Search Advanced Search